Improvements in the prevention of postoperative venous thromboembolism in hip fracture patients

Orthopedics

Volumn 26, Issue 8 SUPPL., 2003, Pages

  Eriksson, Bengt I ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGH RISK PATIENT; HIP ARTHROPLASTY; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VEIN DISEASE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CLINICAL TRIALS, PHASE III; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; FRACTURE FIXATION, INTERNAL; HIP FRACTURES; HUMANS; INCIDENCE; INJURY SEVERITY SCORE; MALE; MIDDLE AGED; POLYSACCHARIDES; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; PRIMARY PREVENTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SEX FACTORS; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0041421031     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc. 1997; 45:281-287.
2. Magaziner J, Lydick E, Hawkes W, et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health. 1997; 87:1630-1636.
3. van Balen R, Steyerberg EW, Polder JJ, Ribbers TL, Habbema JD, Cools HJ. Hip fracture in elderly patients: outcomes for function, quality of life, and type of residence. Clin Orthop. 2001; 9:232-243.
4. Schurch MA, Rizzoli R, Mermillod B, Vasey H, Michel JP, Bonjour JP. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res. 1996; 11:1935-1942.
5. Gillepsie WJ. Hip fracture. BMJ. 2000; 321:968-975.
6. Zuckerman JD. Hip fracture. Lancet. 1996; 334:1519-1525.
7. Kannus P, Niemi S, Parkkari J, Palvanen M, Vuori I, Järvinen M. Hip fractures in Finland between 1970 and 1997 and predictions for the future. Lancet. 1999; 353:802-805.
8. Center JT, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353:878-882.
9. Frostick SP. Death after joint replacement. Haemostasis. 2000; 30:84-87.
10. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001; 119(Suppl):132S-175S.
11. Nicolaides AN. Prevention of venous thromboembolism. European Consensus Statement. Int Angiol. 1997; 16:3-38.
12. Perez JV, Warwick DJ, Case CP, Bannister GC. Death after proximal femoral fracture-an autopsy study. Injury. 1995; 26:237-240.
13. Hefley FG Jr, Nelson CL, Puskarich-May CL. Effect of delayed admission to the hospital on the preoperative prevalence of deep-vein thrombosis associated with fractures about the hip. J Bone Joint Surg Am. 1996; 78:581-583.
14. Morrison RS, Chassin MR, Siu AL. The medical consultant's role in caring for patients with hip fracture. Ann Intern Med. 1998; 128:1010-1020.
15. Urwin SC, Parker MJ, Griffiths R. General versus regional anaesthesia for hip fracture surgery: a meta-analysis of randomized trials. Br J Anaesth. 2000; 84:450-455.
16. Fisher CG, Blachut PA, Salvian AJ, Meek N, O'Brien PJ. Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomized study of compression alone versus no prophylaxis. J Orthop Trauma. 1995; 9:1-7.
17. Hartman JT, Pugh JL, Smith RD, Robertson WW Jr, Yost RP, Janssen HF. Cyclic sequential compression of the lower limbs in prevention of deep venous thrombosis. J Bone Joint Surg Am. 1982; 64:1059-1062.
18. Moskovitz PA, Ellenberg SS, Feffer HL, et al. Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg Am. 1978; 60:1065-1070.
19. Monreal M, Lafoz E, Navarro A, et al. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma. 1989; 29:873-875.
20. Lassen MR, Borris LC, Poulsen KA, Jenssen HP. Thromboembolic complications after hip fracture. Prophylaxis with LMWH versus unfractionated heparin. Thromb Haemost. 1995; 73:1104.
21. Barsotti J, Gruel Y, Rosset P, et al. Comparative double-blind study of two dosage regimens of low-molecular-weight heparin in elderly patients with a fracture of the neck of the femur. J Orthop Trauma. 1990; 4:371-375.
22. Thromboprophylaxis in hip fracture surgery. A pilot study comparing danaparoid, enoxaparin and dalteparin. The TIFDED Study Group. Haemostasis. 1999; 29:310-317.
23. Jorgensen PS, Strandberg C, Wille-Jorgensen P, et al. Early preoperative thromboprophylaxis with Klexane in hip fracture surgery: a placebo-controlled trial. Clin Appl Thrombosis/Hemostasis. 1998; 4:140-142.
24. Agnelli G, Cosmi B, Di Filippo P, et al. A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost. 1992; 67:203-208.
25. Bergqvist D, Kettunen K, Fredin H, et al. Thromboprophylaxis in patients with hip fractures: a prospective, randomized, comparative study between ORG 10172 and dextran 70. Surgery. 1991; 109:617-622.
26. Gent M, Hirsh J, Ginsberg JS, et al. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation. 1996; 93:80-84.
27. Gerhart TN, Yett HS, Robertson LK, Lee MA, Smith M, Salzman EW. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial. J Bone Joint Surg Am. 1991; 73:494-502.
28. Borgstrom S, Greitz T, Van Der Linden W, et al. Anticoagulant prophylaxis of venous thrombosis in patients with fractured neck of the femur. Acta Chir Scand. 1965; 129:500-508.
29. Hamilton HW, Crawford JS, Gardiner JH, Wiley AM. Venous thrombosis in patients with fracture of the upper end of the femur. J Bone Joint Surg Br. 1970; 52:268-289.
30. Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med. 1989; 149:771-774.
31. Bronge A, Dahlgren S, Lindquist B. Prophylaxis against thrombosis in femoral neck fractures-a comparison between dextran 70 and dicumarol. Acta Chir Scand. 1971; 137:29-35.
32. Bergquist E, Bergqvist D, Bronge A, Lindquist B. An evaluation of early, thrombosis prophylaxis following fracture of the femoral neck. A comparison between dextran and dicoumarol. Acta Chir Scand. 1972; 138:689-693.
33. No authors listed. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355:1295-1302.
34. Collaborative overview of randomized trials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ. 1994; 308:235-246.
35. Cohen AT, Bailey CS, Alikhan R, Cooper DJ. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty-a meta-analysis. Thromb Haemost. 2001; 85:940-941.
36. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001; 358:9-15.
37. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002; 346:975-980.
38. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998; 158:1525-1531.
39. Wilson D, Cooke EA, McNally MA, Wilson HK, Yeates A, Mollan RA. Changes in coagulability as measured by thrombelastography following surgery for proximal femoral fracture. Injury. 2001; 32:765-770.
40. Herbert JM, Petitou M, Lormeau JC, et al. SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev. 1997; 15:1-26.
41. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR90107/ORG31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost. 1995; 74:1474-1477.
42. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001; 344:619-625.
43. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001; 345:1298-1304.
44. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001; 345:1305-1310.
45. Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002; 359:1715-1720.
46. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002; 359:1721-1726.
47. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. A multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. (in press).
48. Donat F, Diner JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. 2002; 41(Suppl):1-9.
49. Davidson BL. What are the most reliable detection methods for deep vein thrombosis and pulmonary embolism to be used as endpoints in trials of venous thromboprophylaxis? Haemostasis. 1998; 28(Suppl 3):113-119.
50. Kearon C, Julian JA, Math M, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. Ann Intern Med. 1998;128:663-677.
51. Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel J-P. Low molecular weight heparin in prevention of postoperative thrombosis. BMJ. 1992; 305:913-920.
52. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992; 340:152-156.
53. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized studies. Arch Intern Med. 2002; 162;1833-1840.
54. Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med. 2002; 162:1451-1456.
55. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996; 348:224-228.
56. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost. 1997; 77:26-31.
57. Hull RD, Pineo GF, Francis C. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med. 2000; 160:2208-2215.
58. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996; 335:696-700.
59. Elalamy I, Lecrubier C, Potevin F, et al Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost. 1995; 74:1384-1385.
60. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR91107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coag Fibrinolysis. 1997; 8:114-117.
61. Havig Ö. Deep vein thrombosis and pulmonary embolism. An autopsy study with multiple regression analysis of possible risk factors. Acta Chir Scand. 1977; 478 (Suppl):1-120.
62. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med. 1981; 94:439-444.